Japan’s Drug Regulation During the COVID‐19 Pandemic: Lessons From a Case Study of Favipiravir
Munetaka Ueda, Tetsuya Tanimoto, Anju Murayama, Akihiko Ozaki, Masahiro Kami
Abstract
T.T. reported personal fees from Medical Network Systems, MNES Inc. and Bionics Co., Ltd. A.O. reported personal fees from Medical Network Systems, MNES Inc. M.K. reported personal fees from SBI Biotech Co., Ltd. All other authors declared no competing interests for this work.
Topics & Concepts
FavipiravirCoronavirus disease 2019 (COVID-19)PandemicPersonal protective equipmentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Work (physics)2019-20 coronavirus outbreakBusinessVirologyMedicineOutbreakEngineeringInfectious disease (medical specialty)PathologyDiseaseMechanical engineeringCOVID-19 Clinical Research StudiesTuberculosis Research and EpidemiologyPharmacovigilance and Adverse Drug Reactions